CS
KLRS

Credit Suisse’s Kalaris Therapeutics KLRS Stock Holding History

Credit Suisse’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,283
Closed -$113K – 3162
2023
Q3 		$113K Sell
2,283
-132
-5% -$8.99K ﹤0.01% 3088
2023
Q2 		$189K Buy
2,415
+590
+32% +$56.1K ﹤0.01% 3099
2023
Q1 		$165K Buy
1,825
+208
+13% +$26.5K ﹤0.01% 3151
2022
Q4 		$191K Buy
1,617
+295
+22% +$50K ﹤0.01% 3197
2022
Q3 		$239K Buy
1,322
+225
+21% +$35.1K ﹤0.01% 3178
2022
Q2 		$98K Buy
1,097
+37
+3% +$3.88K ﹤0.01% 3536
2022
Q1 		$164K Buy
1,060
+72
+7% +$14.4K ﹤0.01% 3418
2021
Q4 		$293K Sell
988
-168
-15% -$77.9K ﹤0.01% 4121
2021
Q3 		$667K Buy
1,156
+361
+45% +$167K ﹤0.01% 3622
2021
Q2 		$361K Buy
795
+313
+65% +$162K ﹤0.01% 4021
2021
Q1 		$258K Sell
482
-640
-57% -$538K ﹤0.01% 4044
2020
Q4 		$991K Buy
+1,122
New +$863K ﹤0.01% 3349

Other funds holding KLRS

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return

Credit Suisse's KLRS Position: Q4 2023 in Review

Credit Suisse sold out of Kalaris Therapeutics (KLRS) in Q4 2023, closing a stake of 2,283 shares — an estimated $113K sold.

Credit Suisse first reported a position in KLRS in Q4 2020 and held it in 12 quarters. The position peaked at $991K in Q4 2020. 81 funds tracked by Wall St. Rank hold KLRS as of Q4 2023.

  • Credit Suisse reported no remaining Kalaris Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Credit Suisse sold 2,283 Kalaris Therapeutics shares in Q4 2023, an estimated $113K.
  • Credit Suisse first reported a position in Kalaris Therapeutics in Q4 2020 and held it in 12 quarters.
  • Credit Suisse's Kalaris Therapeutics position peaked at $991K in Q4 2020.
  • 81 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2023.

Based on Credit Suisse's 13F filing for Q4 2023, filed 8 Feb 2024.